Metagenomi, Inc. Common Stock

Metagenomi Therapeutics, Inc. is an in vivo genome editing company that develops curative genetic medicines in the United States. Its lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. The company has a collaboration agreement with Ionis Pharmaceuticals, Inc. covering apolipoprotein C-III for hypertriglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. Formerly known as Metagenomi, Inc., it changed its name to Metagenomi Therapeutics, Inc. in January 2026; it was incorporated in 2016 and is headquartered in Emeryville, California.

Biotech & Genomic Medicine▼

Metagenomi Reports Wider Q2 Loss as MGX-001 Advances Toward IND Submission

Metagenomi Therapeutics posted a second-quarter net loss of $27.48 million, or $0.73 per share, compared with a loss of $19.91 million, or $0.54 per share, a year earlier. The wider loss reflected a $0.26 million loss from collaborations, versus an $8.51 million gain in the prior-year period, while research and development expenses were essentially flat at $22.51 million. The company ended the quarter with $120.66 million in cash, cash equivalents, and marketable securities. Metagenomi is advancing MGX-001, a CRISPR-based therapy for Hemophilia A, toward an investigational new drug submission planned for the fourth quarter, with clinical trials expected to begin in 2027.

MGX ▼

Biotech & Genomic Medicine

RTTNews·38dRead more →